Stay updated with breaking news from Ancora Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EmbarkNeuro, a neuroscience biotech company formerly known as Ancora Bio, announced its phase 2 trial is under way for ANC-501, a first-in-class vasopressin 1b receptor antagonist for the treatment of major depressive disorder. The trial, an 8-week single-arm study, will assess the efficacy of ANC-501 when added to a standard antidepressant therapy in patients with biomarker-confirmed disruption
CHICAGO — Evidence suggests that selective laser trabeculoplasty could be the standard of care for patients with glaucoma, according to a speaker here.
Share this article Share this article OAKLAND, Calif., June 30, 2021 /PRNewswire/ -- Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, today announced the formation of Ancora Bio, a portfolio company developing a new therapy for treatment-resistant depression. Ancora Bio is being formed following the successful in-licensing of a selective vasopressin 1b receptor (V1b) antagonist (ANC-501) from Taisho Pharmaceutical Co., Ltd. "Depression is unfortu...